August 23, 2013

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

.   .   

This randomized double-blind noninferiority trial compared the 18-month efficacy of rituximab + placebo vs cyclophosphamide + azathioprine for the treatment of ANCA-associated vasculitis. Of the 197 patients enrolled, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. The results were similar at 12 and 18 months. The authors concluded that both regimens were effective as both induction and maintenance therapies for ANCA-associated vasculitis over 18 months of follow-up.

Related Articles:

Clinical Nephrology, General Nephrology, Glomerulonephritis